Metabolites associated with transaminitis in a discovery cohort (N = 234) and detected in a replication cohort (N = 80) of pediatric patients treated for ALL at Texas Children’s Hospital, 2007 to 2018
| Metabolite . | Discovery . | Replication . | Combined . | |||
|---|---|---|---|---|---|---|
| OR (95% CI) . | P value . | OR (95% CI) . | P value . | OR (95% CI) . | P value . | |
| 1-Linoleoylglycerol (18:3) | 0.26 (0.09-0.67) | .009 | 0.78 (0.26-1.60) | .60 | 0.48 (0.24-0.93) | .03 |
| 1,2-Dipalmitoyl-GPC (16:0/16:0) | 1.79 (1.15-2.9) | .013 | 2.15 (1.10-5.26) | .042 | 1.88 (1.26-2.79) | .0019 |
| 1-Linoleoylglycerol (18:2) | 0.36 (0.15-0.77) | .014 | 0.75 (0.20-1.56) | .62 | 0.48 (0.25-0.91) | .02 |
| 1-Palmitoleoylglycerol (16:1)∗ | 0.08 (0.008-0.056) | .018 | 0.68 (0.21- 1.82) | .47 | 0.21 (0.10-0.43) | <.0001 |
| 1-(1-Enyl-palmitoyl)-2-palmitoleoyl-GPC (P-16:0/16:1)∗ | 1.42 (1.06-2.00) | .025 | 2.60 (1.30-5.65) | .011 | 1.56 (1.17-2.09) | .0026 |
| Tetradecanedioate (C14-DC) | 1.45 (1.07- 2.07) | .026 | 1.53 (0.92-3.06) | .15 | 1.47 (1.10-1.96) | .009 |
| Citrulline | 1.61 (1.06-2.50) | .027 | 0.79 (0.42-1.44) | .46 | 1.28 (0.90-1.81) | .17 |
| Hexadecanedioate (C16-DC) | 1.48 (1.06-2.48) | .031 | 1.57 (0.95-2.84) | .094 | 1.51 (1.08-2.12) | .016 |
| Cystathionine | 3.10 (1.10-10.06) | .042 | 1.41 (0.77- 2.60) | .25 | 1.69 (0.99-2.88) | .056 |
| Oleoyl-linoleoylglycerol (18:1/18:2) [1] | 0.71 (0.50-0.98) | .044 | 1.38 (0.72-2.72) | .32 | 0.81 (0.60-1.10) | .18 |
| Gamma-tocopherol/beta-tocopherol | 0.71 (0.48-0.98) | .044 | 0.71 (0.31-1.39) | .37 | 0.71 (0.51-0.98) | .037 |
| Bilirubin (Z,Z) | 1.57 (1.02-2.49) | .044 | 0.78 (0.35-1.51) | .51 | 1.30 (0.89-1.90) | .18 |
| Metabolite . | Discovery . | Replication . | Combined . | |||
|---|---|---|---|---|---|---|
| OR (95% CI) . | P value . | OR (95% CI) . | P value . | OR (95% CI) . | P value . | |
| 1-Linoleoylglycerol (18:3) | 0.26 (0.09-0.67) | .009 | 0.78 (0.26-1.60) | .60 | 0.48 (0.24-0.93) | .03 |
| 1,2-Dipalmitoyl-GPC (16:0/16:0) | 1.79 (1.15-2.9) | .013 | 2.15 (1.10-5.26) | .042 | 1.88 (1.26-2.79) | .0019 |
| 1-Linoleoylglycerol (18:2) | 0.36 (0.15-0.77) | .014 | 0.75 (0.20-1.56) | .62 | 0.48 (0.25-0.91) | .02 |
| 1-Palmitoleoylglycerol (16:1)∗ | 0.08 (0.008-0.056) | .018 | 0.68 (0.21- 1.82) | .47 | 0.21 (0.10-0.43) | <.0001 |
| 1-(1-Enyl-palmitoyl)-2-palmitoleoyl-GPC (P-16:0/16:1)∗ | 1.42 (1.06-2.00) | .025 | 2.60 (1.30-5.65) | .011 | 1.56 (1.17-2.09) | .0026 |
| Tetradecanedioate (C14-DC) | 1.45 (1.07- 2.07) | .026 | 1.53 (0.92-3.06) | .15 | 1.47 (1.10-1.96) | .009 |
| Citrulline | 1.61 (1.06-2.50) | .027 | 0.79 (0.42-1.44) | .46 | 1.28 (0.90-1.81) | .17 |
| Hexadecanedioate (C16-DC) | 1.48 (1.06-2.48) | .031 | 1.57 (0.95-2.84) | .094 | 1.51 (1.08-2.12) | .016 |
| Cystathionine | 3.10 (1.10-10.06) | .042 | 1.41 (0.77- 2.60) | .25 | 1.69 (0.99-2.88) | .056 |
| Oleoyl-linoleoylglycerol (18:1/18:2) [1] | 0.71 (0.50-0.98) | .044 | 1.38 (0.72-2.72) | .32 | 0.81 (0.60-1.10) | .18 |
| Gamma-tocopherol/beta-tocopherol | 0.71 (0.48-0.98) | .044 | 0.71 (0.31-1.39) | .37 | 0.71 (0.51-0.98) | .037 |
| Bilirubin (Z,Z) | 1.57 (1.02-2.49) | .044 | 0.78 (0.35-1.51) | .51 | 1.30 (0.89-1.90) | .18 |
Indicates compounds that have not been officially confirmed based on a standard, but the authors are confident in its identity.